Dosage adjustments in hepatic dysfunction [2]

American Journal of Health-System Pharmacy

Volumn 64, Issue 24, 2007, Pages 2536-2538

  Amariles, Pedro ^a   Lacampa, Patricia ^b   Saez Benito, Loreto ^c  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b Aragon Health Service   (Spain)

^c Pharmaceutical Care Research Group   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; EPLERENONE; LUMIRACOXIB; PARECOXIB; RITONAVIR; TIPRANAVIR; VARDENAFIL; VORICONAZOLE;

DOSE CALCULATION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG INFORMATION; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER DYSFUNCTION; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 37249061650     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070273     Document Type: Letter

References (4)

1. Spray JW, Willett K, Chase D et al. Dosage adjustment for hepatic dysfunction based on Child-Pugh scores. Am J Health-Syst Pharm. 2007; 64:690,692-3. Letter.
2. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf (accessed 2007 Sep 25).
3. European Medicines Agency. EPARs for authorised medicinal products for human use. www.emea.europa.eu/htms/human/epar/a.htm (accessed 2007 Sep 25).
4. Food and Drug Administration. FDA-approved drug products. www.accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 2007 Sep 25).